C-Reactive Protein and Risk of Cardiovascular Events and Mortality in Patients with Various Cardiovascular Disease Locations
P.M. Burger(University Medical Center Utrecht), Frank L.J. Visseren, Arend Mosterd(Werkgroep Cardiologische centra Nederland), Martin Teraa(Maine Farmland Trust), Manon G. van der Meer(University Medical Center Utrecht), Gert J. de Borst(Reinier de Graaf Hospital), Stefan Koudstaal, Paul M. Ridker(Brigham and Women's Hospital), Jannick A N Dorresteijn(Heidelberg University), Aruna D. Pradhan(Brigham and Women's Hospital)
Cited by 66
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
|European Heart Journal|2021|6.1k
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
|New England Journal of Medicine|2002|3.6k
Interpretation of the evidence for the efficacy and safety of statin therapy
|The Lancet|2016|1.8k
Effect of Statin Therapy on C-Reactive Protein Levels
|JAMA|2001|1.7k